New developments in the management of severe skin and deep skin structure infections – Focus on tedizolid

Keyphrases

• Skin Structure Infections 100%
• Infection Focus 100%
• Tedizolid 100%
• Acute Bacterial Skin 30%
• Linezolid 20%
• Treatment Options 10%
• Nausea 10%
• Pharmacokinetics 10%
• Quality of Life 10%
• Enterococcus 10%
• Methicillin-resistant Staphylococcus Aureus 10%
• Patient Satisfaction 10%
• Thrombocytopenia 10%
• Patient-centered 10%
• Coagulase-negative Staphylococci (CoNS) 10%
• Mode of Action 10%
• Delayed Onset 10%
• Oral Formulation 10%
• Expert Opinion 10%
• Future Therapeutics 10%
• Therapeutic Use 10%
• Drug Interactions 10%
• Monoamine Oxidase Inhibitors 10%
• Pharmacology 10%
• Microbiology 10%
• Infection Treatment 10%
• Oral Bioavailability 10%
• Selective Serotonin Reuptake Inhibitors 10%
• Broad-spectrum Activity 10%
• Gram-positive Organisms 10%
• Oxazolidinone 10%
• Once-daily Dosing 10%
• Prolonged Half-life 10%
• Intravenous Formulation 10%
• Oral Step-down 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Infection 100%
• Tedizolid 100%
• Linezolid 20%
• Nausea 10%
• Thrombocytopenia 10%
• Coagulase Negative Staphylococcus 10%
• Enterococcus 10%
• Drug Interaction 10%
• Gram Positive Bacterium 10%
• Bioavailability 10%
• Methicillin-Resistant Staphylococcus Aureus 10%
• Monoamine Oxidase Inhibitor 10%
• Selective Serotonin Reuptake Inhibitor 10%
• Oxazolidinone Derivative 10%
• Pharmacokinetics 10%
• Side Effect 10%